Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system
View/ Open
Date
2018Author
Ammar, Hussein O.
Ghorab, Mahmoud M.
Mahmoud, Azza A.
Higazy, Iman M.
Metadata
Show full item recordAbstract
Management of epilepsy requires brain delivery therapy, therefore, this study was
aimed to prepare lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) (PLCL)
nanoparticles using spontaneous emulsification solvent diffusion method.
Nanoparticles for brain delivery required to have a particle size less than 200 nm,
polydispesity index less than 0.2 and a sustained drug release properties. For such aim
different factors were considered in preparing the nanoparticles as PLCL monomers'
ratio, type of organic solvent used to prepare the nanoparticles, amount of PLCL and
Pluronic®
F127 in the nanoparticles. Prepared nanoparticles were characterized for
their shape, particle size, polydispersity index, zeta potential, encapsulation
efficiency, drug loading capacity, process yield and in-vitro drug release pattern. The
in-vivo investigation for brain delivery of selected nanoparticles delivered by
intravenous route was investigated in rats and compared to that for oral tablet. The
obtained nanoparticles were spherical in shape. The amount of surfactant and PLCL
affected the properties of the obtained nanoparticles. Using a mixture of organic
solvent in preparing the nanoparticles improved its properties. The nanoparticles
prepared using PLCL with monomers' ratio of 25: 75, had particle size value of 125
nm, polydispersity value of 0.184, zeta potential value of -39 mV and encapsulation
efficiency of 99 %, was selected to study its efficacy to deliver the drug to the brain.
The tested nanoparticles showed higher values of Tmax, Cmax, AUC, and MRT in
homogenized rat brain, compared to oral lamotrigine tablet, while the bioavailability
of the oral tablet was higher in rat plasma compared to that for the nanoparticles. This
reflects that brain was the main distribution site for tested nanoparticles, and plasma
was the main distribution site for oral tablets. This confirms the goal of the selected
formulation as brain delivery nanoparticles.
Collections
- Articles [227]